Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 149.74$. Average daily volumn in 3 months 7.28M. Market cap 272.38B



Stock symbol : ABBV. Exchange : NYSE. Currency : USD
Lastest price : 154.14$. Total volume : 599.74k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

AbbVie Inc. (ABBV)
Last Price
154.14$
Change
0.21
Volume
599.74k

Previous Close153.93
Open154.61
Day Range153.76-154.96
Bid154.15 x 900
Ask154.23 x 900
Volume599.74k
Average Volume7.28M
Market Cap272.38B
Beta0.81
52 Week Range105.56-175.91
Trailing P/E22.11
Foward P/E12.89
Dividend (Yield %)3.67%
Ex-Dividend Date2022-07-14



Financial Details


According to AbbVie Inc.'s financial reports the company's revenue in 2021 were 56.2B an increase( +24.44%) over the years 2020 revenue that were of 45.8B. In 2021 the company's total earnings were 11.54B while total earnings in 2020 were 4.62B( +175%).


Loading ...



Organization

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Market Cap:
272.38B
Revenue:
56.2B
Total Assets:
146.53B
Total Cash:
9.75B


News about "AbbVie Inc."

abbvie-inc-nyseabbv-shares-sold-by-waddell-associates-llc-image

AbbVie Inc. (NYSE:ABBV) Shares Sold by Waddell & Associates LLC

Source from : Defense World - 1 days ago

Waddell & Associates LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 23.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The ...See details»


apricus-wealth-llc-reduces-stock-holdings-in-abbvie-inc-nyseabbv-image

apricus wealth LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Source from : Defense World - 1 days ago

LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 8.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...See details»


This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

Source from : Nasdaq - 1 days ago

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be ...See details»


should-you-consider-acquiring-abbvie-abbv-shares-image

Should You Consider Acquiring AbbVie (ABBV) Shares?

Source from : Yahoo! Sports - 2 days ago

Carillon Tower Advisers, an investment management firm, published its โ€œCarillon Clarivest Capital Appreciation Fundโ€ first quarter 2022 investor letter โ€“ a copy of which can be downloaded here. At the ...See details»


when-abbvie-inc-abbv-moves-investors-should-listen-image

When Abbvie Inc (ABBV) Moves Investors should Listen

Source from : news.stocktradersdaily - 3 days ago

When Abbvie Inc ABBV Moves Investors should Listen ...See details»


AbbVie Inc. (ABBV) Outlook: Revisiting The Past For Future Insights

Source from : stocksregister - 6 days ago

AbbVie Inc. (NYSE:ABBV) at last check was buoying at $152.49 on Thursday, June 30, with a fall of -1.07% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


inspirion-wealth-advisors-llc-acquires-14917-shares-of-abbvie-inc-nyseabbv-image

Inspirion Wealth Advisors LLC Acquires 14,917 Shares of AbbVie Inc. (NYSE:ABBV)

Source from : ETF Daily News - 9 days ago

Inspirion Wealth Advisors LLC raised its holdings in AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 6.4% during the first quarter, according to the company in its most recent filing with the Securities & ...See details»


ritholtz-wealth-management-grows-stake-in-abbvie-inc-nyseabbv-image

Ritholtz Wealth Management Grows Stake in AbbVie Inc. (NYSE:ABBV)

Source from : ETF Daily News - 9 days ago

Ritholtz Wealth Management increased its position in AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) by 279.3% in the first quarter, according to the company in its most recent filing with the Securities & ...See details»


abbvies-abbv-rinvoq-gets-chmp-nod-for-new-indication-image

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

Source from : Nasdaq - 9 days ago

ABBV announced that the European Medicines Agencyโ€™s Committee for Medicinal Products for Human Use (โ€œCHMPโ€) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor ...See details»


AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Source from : Yahoo Finance - 20 days ago

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.See details»


us-intrauterine-devices-market-worth-usd-3-billion-by-2030-says-global-market-insights-inc-image

U.S. Intrauterine Devices Market worth USD 3 billion by 2030, says Global Market Insights Inc.

Source from : TMCnet - 1 days ago

U.S. intrauterine devices market value is projected to reach USD 3 billion by 2030, according to a new research report by Global Market Insights Inc. Favorable regulatory scenario along with rising ...See details»


abbvie-rallies-after-its-test-of-the-rising-200-day-moving-average-line-image

AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line

Source from : TheStreet.com - 9 days ago

In this daily bar chart of , below, we can see that prices rallied back above the 50-day moving average line after touching/testing the rising 200-day line earlier this month. The ...See details»


AbbVie Declares Quarterly Dividend

Source from : Associated Press - 13 days ago

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August 15, 2022, to stockholders of record at the close of ...See details»


AbbVie Stockโ€™s Healthy Yield Makes it a High-Conviction Holding

Source from : YAHOO!Finance - 9 days ago

Headquartered in Illinois, AbbVie (NYSE:ABBV) is a well-respected pharmaceutical businesses with a broad range of medical treatments and solutions. If youโ€™re going to pick a pharmaceutical-market ...See details»